130 related articles for article (PubMed ID: 22371553)
21. Nrf2 expression is associated with poor outcome in osteosarcoma.
Park JY; Kim YW; Park YK
Pathology; 2012 Dec; 44(7):617-21. PubMed ID: 23172081
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of P-glycoprotein, HER-2/ErbB-2, p53, and Bcl-2 in primary tumor and metachronous lung metastases in patients with high-grade osteosarcoma.
Ferrari S; Bertoni F; Zanella L; Setola E; Bacchini P; Alberghini M; Versari M; Bacci G
Cancer; 2004 May; 100(9):1936-42. PubMed ID: 15112275
[TBL] [Abstract][Full Text] [Related]
23. Treatment and prognosis for synchronous multifocal osteosarcoma in 42 patients.
Bacci G; Fabbri N; Balladelli A; Forni C; Palmerini E; Picci P
J Bone Joint Surg Br; 2006 Aug; 88(8):1071-5. PubMed ID: 16877608
[TBL] [Abstract][Full Text] [Related]
24. [Primary chemotherapy with the Rosen T10 protocol before conservative surgery in limb primitive osteosarcomas: results about 56 cases].
Boussen H; Mezzi F; Gamoudi A; Daldoul O; Ben Hamida H; Mezlini A; Khalfallah S; Karray S; Ben Romdhane K; Ben Ghachem M; Ben Abdallah M; Douik M; Saadi A; Ben Ayed F; Ben Hassine H
Bull Cancer; 2000 Feb; 87(2):183-8. PubMed ID: 10705289
[TBL] [Abstract][Full Text] [Related]
25. Neoadjuvant chemotherapy for osteosarcoma of the extremities in preadolescent patients: the Rizzoli Institute experience.
Bacci G; Balladelli A; Palmerini E; Alberghini M; Pollastri P; Galletti S; Mercuri M; Picci P
J Pediatr Hematol Oncol; 2008 Dec; 30(12):908-12. PubMed ID: 19131777
[TBL] [Abstract][Full Text] [Related]
26. Osteosarcoma of the pelvis. Oncologic results of 40 patients.
Kawai A; Huvos AG; Meyers PA; Healey JH
Clin Orthop Relat Res; 1998 Mar; (348):196-207. PubMed ID: 9553553
[TBL] [Abstract][Full Text] [Related]
27. Can cure in patients with osteosarcoma be achieved exclusively with chemotherapy and abrogation of surgery?
Jaffe N; Carrasco H; Raymond K; Ayala A; Eftekhari F
Cancer; 2002 Nov; 95(10):2202-10. PubMed ID: 12412175
[TBL] [Abstract][Full Text] [Related]
28. Telangiectatic osteosarcoma of the extremity: neoadjuvant chemotherapy in 24 cases.
Bacci G; Ferrari S; Ruggieri P; Biagini R; Fabbri N; Campanacci L; Bacchini P; Longhi A; Forni C; Bertoni F
Acta Orthop Scand; 2001 Apr; 72(2):167-72. PubMed ID: 11372948
[TBL] [Abstract][Full Text] [Related]
29. Comparative proteomics analysis of human osteosarcomas and benign tumor of bone.
Li Y; Liang Q; Wen YQ; Chen LL; Wang LT; Liu YL; Luo CQ; Liang HZ; Li MT; Li Z
Cancer Genet Cytogenet; 2010 Apr; 198(2):97-106. PubMed ID: 20362224
[TBL] [Abstract][Full Text] [Related]
30. Skip metastases in osteosarcoma: experience of the Cooperative Osteosarcoma Study Group.
Kager L; Zoubek A; Kastner U; Kempf-Bielack B; Potratz J; Kotz R; Exner GU; Franzius C; Lang S; Maas R; Jürgens H; Gadner H; Bielack S;
J Clin Oncol; 2006 Apr; 24(10):1535-41. PubMed ID: 16575004
[TBL] [Abstract][Full Text] [Related]
31. Osteosarcomas after the age of 50: a clinicopathologic study of 64 cases--an experience in northern Japan.
Okada K; Hasegawa T; Nishida J; Ogose A; Tajino T; Osanai T; Yanagisawa M; Hatori M
Ann Surg Oncol; 2004 Nov; 11(11):998-1004. PubMed ID: 15525829
[TBL] [Abstract][Full Text] [Related]
32. RANKL expression is related to treatment outcome of patients with localized, high-grade osteosarcoma.
Lee JA; Jung JS; Kim DH; Lim JS; Kim MS; Kong CB; Song WS; Cho WH; Jeon DG; Lee SY; Koh JS
Pediatr Blood Cancer; 2011 May; 56(5):738-43. PubMed ID: 21370405
[TBL] [Abstract][Full Text] [Related]
33. Expression of heat shock proteins in osteosarcomas.
Moon A; Bacchini P; Bertoni F; Olvi LG; Santini-Araujo E; Kim YW; Park YK
Pathology; 2010; 42(5):421-5. PubMed ID: 20632817
[TBL] [Abstract][Full Text] [Related]
34. [Prognostic factors for the local recurrence of osteosarcoma in extremities treated with combined therapy].
Zhang Q; Niu XH; Cai YB; Hao L; Ding Y
Zhonghua Wai Ke Za Zhi; 2007 Aug; 45(16):1114-7. PubMed ID: 18005614
[TBL] [Abstract][Full Text] [Related]
35. Bone metastases in osteosarcoma patients treated with neoadjuvant or adjuvant chemotherapy: the Rizzoli experience in 52 patients.
Bacci G; Longhi A; Bertoni F; Briccoli A; Versari M; Pignotti E; Picci P
Acta Orthop; 2006 Dec; 77(6):938-43. PubMed ID: 17260205
[TBL] [Abstract][Full Text] [Related]
36. Expression of c-kit in human osteosarcoma and its relevance as a prognostic marker.
Sulzbacher I; Birner P; Toma C; Wick N; Mazal PR
J Clin Pathol; 2007 Jul; 60(7):804-7. PubMed ID: 17018686
[TBL] [Abstract][Full Text] [Related]
37. An expression signature classifies chemotherapy-resistant pediatric osteosarcoma.
Mintz MB; Sowers R; Brown KM; Hilmer SC; Mazza B; Huvos AG; Meyers PA; Lafleur B; McDonough WS; Henry MM; Ramsey KE; Antonescu CR; Chen W; Healey JH; Daluski A; Berens ME; Macdonald TJ; Gorlick R; Stephan DA
Cancer Res; 2005 Mar; 65(5):1748-54. PubMed ID: 15753370
[TBL] [Abstract][Full Text] [Related]
38. [Expression and significance of N-cadherin and β-catenin protein in osteosarcoma].
Yang JZ; Zhang XH; Liu JR; Ding Y; Gao F; Wang Y
Zhonghua Zhong Liu Za Zhi; 2010 Aug; 32(8):586-9. PubMed ID: 21122409
[TBL] [Abstract][Full Text] [Related]
39. Expression of P-glycoprotein in high grade osteosarcomas with special emphasis on chondroblastic subtype.
Radig K; Häckel C; Herting J; Oda Y; Mittler U; Neumann W; Roessner A
Gen Diagn Pathol; 1997 Feb; 142(3-4):139-45. PubMed ID: 9065577
[TBL] [Abstract][Full Text] [Related]
40. Peroxiredoxin 2 as a chemotherapy responsiveness biomarker candidate in osteosarcoma revealed by proteomics.
Kikuta K; Tochigi N; Saito S; Shimoda T; Morioka H; Toyama Y; Hosono A; Suehara Y; Beppu Y; Kawai A; Hirohashi S; Kondo T
Proteomics Clin Appl; 2010 May; 4(5):560-7. PubMed ID: 21137073
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
